Literature DB >> 18166613

Diffuse neurofibrillary tangles with calcification (DNTC): Kosaka-Shibayama disease in America.

Sudip Nanda1, Surya Prakash Bhatt, John Pamula, William W Woodruff, Martin Fowler, Donna Miller.   

Abstract

Alzheimer's disease and Pick's disease are representative dementias. Cases which do not fit prototypes are termed unclassifiable dementias. New dementia subtypes are identified when a conglomerate of clinical, radiologic and pathologic findings are consistently identified. One such variant is diffuse neurofibrillary tangles with calcification (DNTC), which has been reported almost exclusively from Japan. Significant pathological advances in this decade have established DNTC as a distinct entity. Although initially the diagnosis was neuropathologic, increasing knowledge about DNTC has made it possible for a clinical diagnosis to be made. We report a clinical case of DNTC in a Caucasian American. The diagnosis of DNTC was based on his atypical senile dementia, anomia, apathy and parkinsonian features, normal serum biochemistry, and evidence of basal ganglia and cerebellar calcification with predominant temporal lobe atrophy on neuroimaging. To the best of our knowledge, this is the first clinical description of DNTC from the United States.

Entities:  

Mesh:

Year:  2007        PMID: 18166613     DOI: 10.1177/1533317507312270

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  2 in total

Review 1.  Neuropathological background of phenotypical variability in frontotemporal dementia.

Authors:  Keith A Josephs; John R Hodges; Julie S Snowden; Ian R Mackenzie; Manuela Neumann; David M Mann; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2011-05-26       Impact factor: 17.088

Review 2.  Fahr's disease presenting with dementia at onset: a case report and literature review.

Authors:  Rocco Salvatore Calabrò; Letteria Spadaro; Angela Marra; Placido Bramanti
Journal:  Behav Neurol       Date:  2014-03-12       Impact factor: 3.342

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.